An anti-doxorubicin monoclonal antibody modulates kinetic and dynamic characteristics of the drug

A. Sardini, E. Villa, D. Morelli, M. Ghione, S. Menard, M. I. Colnaghi, A. Balsari

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

A monoclonal antibody (MAb) directed against doxorubicin (DXR), denominated MAD11, was found to exert an antidotal action by modulating the kinetic and dynamic characteristics of the drug. In vitro, MAD11 has been found to reduce the cytotoxicity of DXR and the drug uptake on spleen lymphocytes more efficiently than on tumor cells (P388 leukemia cells). In vivo, the anti-DXR MAb modified the drug distribution; the drug uptake was found to be reduced in the intestine and myocardial tissues and increased in the tumor, liver and spleen. In mice treated with DXR, the administration of anti-DXR MAb exerted an antidotal activity which was proved by the reduction in body-weight loss and mortality. In contrast, the therapeutic efficacy of the drug in P388-tumor-bearing mice was not influenced by the anti-DXR MAb.

Original languageEnglish
Pages (from-to)617-620
Number of pages4
JournalInternational Journal of Cancer
Volume50
Issue number4
Publication statusPublished - 1992

Fingerprint

Doxorubicin
Monoclonal Antibodies
Pharmaceutical Preparations
Spleen
Leukemia P388
Neoplasms
Intestines
Weight Loss
Body Weight
Lymphocytes
Mortality
Liver

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Sardini, A., Villa, E., Morelli, D., Ghione, M., Menard, S., Colnaghi, M. I., & Balsari, A. (1992). An anti-doxorubicin monoclonal antibody modulates kinetic and dynamic characteristics of the drug. International Journal of Cancer, 50(4), 617-620.

An anti-doxorubicin monoclonal antibody modulates kinetic and dynamic characteristics of the drug. / Sardini, A.; Villa, E.; Morelli, D.; Ghione, M.; Menard, S.; Colnaghi, M. I.; Balsari, A.

In: International Journal of Cancer, Vol. 50, No. 4, 1992, p. 617-620.

Research output: Contribution to journalArticle

Sardini, A, Villa, E, Morelli, D, Ghione, M, Menard, S, Colnaghi, MI & Balsari, A 1992, 'An anti-doxorubicin monoclonal antibody modulates kinetic and dynamic characteristics of the drug', International Journal of Cancer, vol. 50, no. 4, pp. 617-620.
Sardini, A. ; Villa, E. ; Morelli, D. ; Ghione, M. ; Menard, S. ; Colnaghi, M. I. ; Balsari, A. / An anti-doxorubicin monoclonal antibody modulates kinetic and dynamic characteristics of the drug. In: International Journal of Cancer. 1992 ; Vol. 50, No. 4. pp. 617-620.
@article{58bf44f0b1724ed5bd1e2b6d3143ad9c,
title = "An anti-doxorubicin monoclonal antibody modulates kinetic and dynamic characteristics of the drug",
abstract = "A monoclonal antibody (MAb) directed against doxorubicin (DXR), denominated MAD11, was found to exert an antidotal action by modulating the kinetic and dynamic characteristics of the drug. In vitro, MAD11 has been found to reduce the cytotoxicity of DXR and the drug uptake on spleen lymphocytes more efficiently than on tumor cells (P388 leukemia cells). In vivo, the anti-DXR MAb modified the drug distribution; the drug uptake was found to be reduced in the intestine and myocardial tissues and increased in the tumor, liver and spleen. In mice treated with DXR, the administration of anti-DXR MAb exerted an antidotal activity which was proved by the reduction in body-weight loss and mortality. In contrast, the therapeutic efficacy of the drug in P388-tumor-bearing mice was not influenced by the anti-DXR MAb.",
author = "A. Sardini and E. Villa and D. Morelli and M. Ghione and S. Menard and Colnaghi, {M. I.} and A. Balsari",
year = "1992",
language = "English",
volume = "50",
pages = "617--620",
journal = "International Journal of Cancer",
issn = "0020-7136",
publisher = "Wiley-Liss Inc.",
number = "4",

}

TY - JOUR

T1 - An anti-doxorubicin monoclonal antibody modulates kinetic and dynamic characteristics of the drug

AU - Sardini, A.

AU - Villa, E.

AU - Morelli, D.

AU - Ghione, M.

AU - Menard, S.

AU - Colnaghi, M. I.

AU - Balsari, A.

PY - 1992

Y1 - 1992

N2 - A monoclonal antibody (MAb) directed against doxorubicin (DXR), denominated MAD11, was found to exert an antidotal action by modulating the kinetic and dynamic characteristics of the drug. In vitro, MAD11 has been found to reduce the cytotoxicity of DXR and the drug uptake on spleen lymphocytes more efficiently than on tumor cells (P388 leukemia cells). In vivo, the anti-DXR MAb modified the drug distribution; the drug uptake was found to be reduced in the intestine and myocardial tissues and increased in the tumor, liver and spleen. In mice treated with DXR, the administration of anti-DXR MAb exerted an antidotal activity which was proved by the reduction in body-weight loss and mortality. In contrast, the therapeutic efficacy of the drug in P388-tumor-bearing mice was not influenced by the anti-DXR MAb.

AB - A monoclonal antibody (MAb) directed against doxorubicin (DXR), denominated MAD11, was found to exert an antidotal action by modulating the kinetic and dynamic characteristics of the drug. In vitro, MAD11 has been found to reduce the cytotoxicity of DXR and the drug uptake on spleen lymphocytes more efficiently than on tumor cells (P388 leukemia cells). In vivo, the anti-DXR MAb modified the drug distribution; the drug uptake was found to be reduced in the intestine and myocardial tissues and increased in the tumor, liver and spleen. In mice treated with DXR, the administration of anti-DXR MAb exerted an antidotal activity which was proved by the reduction in body-weight loss and mortality. In contrast, the therapeutic efficacy of the drug in P388-tumor-bearing mice was not influenced by the anti-DXR MAb.

UR - http://www.scopus.com/inward/record.url?scp=0026539380&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026539380&partnerID=8YFLogxK

M3 - Article

C2 - 1537626

AN - SCOPUS:0026539380

VL - 50

SP - 617

EP - 620

JO - International Journal of Cancer

JF - International Journal of Cancer

SN - 0020-7136

IS - 4

ER -